Gene Therapy in Neurological Disorders
Editat de Mingjie Li, B. Joy Snideren Limba Engleză Hardback – 29 mai 2018
- Provides background information and experimental details of gene therapy tools applied for neuroscience research and neurological disorders
- Covers a broad range of gene delivery and regulation tools, therapeutic agents, and target cells, including emerging new technologies such as CRISPR/Cas9 genome editing
- Discusses applications of gene therapy tools to neurological disorders including neurodegeneration, muscular dystrophy, trauma and chronic pain, and neoplastic diseases
Preț: 729.04 lei
Preț vechi: 885.16 lei
-18% Nou
Puncte Express: 1094
Preț estimativ în valută:
139.52€ • 144.93$ • 115.89£
139.52€ • 144.93$ • 115.89£
Carte tipărită la comandă
Livrare economică 27 ianuarie-10 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780128098134
ISBN-10: 0128098139
Pagini: 450
Dimensiuni: 191 x 235 x 32 mm
Editura: ELSEVIER SCIENCE
ISBN-10: 0128098139
Pagini: 450
Dimensiuni: 191 x 235 x 32 mm
Editura: ELSEVIER SCIENCE
Public țintă
researchers and clinical practitioners in neurology, translational neuroscience, and gene therapiesCuprins
Section I Overview and Methods 1. Gene therapy methods and their applications in neurological disorders 2. Targeting transgene and RNA interference-based gene silencing sequences to astrocytes using viral vector-mediated approaches 3. Gene therapy using genomic DNA: Advances and challenges 4. Stem cell-based gene therapy in neurological disorders
Section II Approaches to specific disorders 5. Targeting astrocytes with viral gene therapy for Alzheimer's disease 6. Prophylactic and therapeutic applications of catalytic immunoglobulin gene delivery in a mouse model of Alzheimer's disease 7. Lentiviral vector delivery of orexin gene to study potential role of orexin and sleep modulation in the pathogenesis of Alzheimer’s disease 8. Pharmacologically controlled neurotrophic factor gene therapy for Parkinson´s Disease 9. Gene therapy as a novel target for treatment of symptoms and medication complications in Parkinson’s disease 10. Inhibition of aggregation of mutant huntingtin by nucleic acid aptamers in vitro and in a yeast model of Huntington’s disease 11. Intraspinal delivery of recombinant AAV mediated Interleukin-10 modifies disease in ALS mice. 12. Differentiation of human induced pluripotent stem cells to Purkinje neurons 13. Expressing full-length dystrophin using adeno-associated virus 14. Genome editing therapy for Duchenne muscular dystrophy 15. AAV vector mediated gene delivery to neurons and glial cells in damaged spinal cord 16. Transplantation of human induced pluripotent stem cell-derived neural precursor cells for treatment of spinal cord injury 17. Viral transduction of primary Schwann cells using a Cre-lox system to regulate GDNF expression 18. Application of Herpes simplex virus vectors in treatment of neuropathic pain 19. Oncolytic virotherapy for gliomas: a preclinical and clinical summary
Section II Approaches to specific disorders 5. Targeting astrocytes with viral gene therapy for Alzheimer's disease 6. Prophylactic and therapeutic applications of catalytic immunoglobulin gene delivery in a mouse model of Alzheimer's disease 7. Lentiviral vector delivery of orexin gene to study potential role of orexin and sleep modulation in the pathogenesis of Alzheimer’s disease 8. Pharmacologically controlled neurotrophic factor gene therapy for Parkinson´s Disease 9. Gene therapy as a novel target for treatment of symptoms and medication complications in Parkinson’s disease 10. Inhibition of aggregation of mutant huntingtin by nucleic acid aptamers in vitro and in a yeast model of Huntington’s disease 11. Intraspinal delivery of recombinant AAV mediated Interleukin-10 modifies disease in ALS mice. 12. Differentiation of human induced pluripotent stem cells to Purkinje neurons 13. Expressing full-length dystrophin using adeno-associated virus 14. Genome editing therapy for Duchenne muscular dystrophy 15. AAV vector mediated gene delivery to neurons and glial cells in damaged spinal cord 16. Transplantation of human induced pluripotent stem cell-derived neural precursor cells for treatment of spinal cord injury 17. Viral transduction of primary Schwann cells using a Cre-lox system to regulate GDNF expression 18. Application of Herpes simplex virus vectors in treatment of neuropathic pain 19. Oncolytic virotherapy for gliomas: a preclinical and clinical summary